From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing-remitting (RR) and secondary progressive (SP) stages of the illness, Campath-1H reduced the annual relapse rate (from 2.2 to 0.19 and from 0.7 to 0.001 respectively; both p < 0.001). Remarkably, MRI scans of patients with SP disease, treated with Campath-1H 7 years previously, showed no new lesion formation. However, despite these effects on inflammation, disability was differently affected depending on the phase of the disease. Patients with SPMS showed sustained accumulation of disabili...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and the most co...
Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune ce...
Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and so...
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal a...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may not be ass...
Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous syst...
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative dis...
BACKGROUND: Multiple sclerosis results from T-cell-dependent inflammatory demyelination of the centr...
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets ...
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common cau...
Multiple Sclerosis is a chronic immune-mediated inflammatory disease of the Central nervous system, ...
Multiple sclerosis is a potentially debilitating disease of the central nervous system. A concerted ...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and the most co...
Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune ce...
Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and so...
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal a...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may not be ass...
Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous syst...
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative dis...
BACKGROUND: Multiple sclerosis results from T-cell-dependent inflammatory demyelination of the centr...
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets ...
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common cau...
Multiple Sclerosis is a chronic immune-mediated inflammatory disease of the Central nervous system, ...
Multiple sclerosis is a potentially debilitating disease of the central nervous system. A concerted ...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and the most co...
Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune ce...
Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and so...